Billionaire Profile
Christoph Boehringer
Global Rank
#605

Image: Phaeton1 | CC BY-SA 3.0 | via Wikimedia Commons

Christoph Boehringer

CEO, Pharmaceuticals
GERMANY
Real-Time Net Worth
$6.538B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
0% (24h)
Age
55
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
GERMANY

Biography

Christoph Boehringer, a prominent figure in the pharmaceutical industry, owes his considerable wealth to his stake in Boehringer Ingelheim, a leading global pharmaceutical company. At 55 years old, Christoph Boehringer's estimated net worth is $5.9 billion, placing him among the world's wealthiest individuals. His career has been dedicated to the healthcare sector, where Boehringer Ingelheim has been a driving force in the development of innovative medicines and treatments. The Boehringer family, which includes Christoph, has a long-standing legacy of scientific excellence and commitment to improving human health. His focus has been in the core business of pharmaceuticals, which encompasses the research, development, and commercialization of various medical solutions.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life and Family Heritage

Christoph Boehringer is part of the Boehringer and von Baumbach families, who control Boehringer Ingelheim. The company's roots trace back to 1885 when Albert Boehringer founded a small factory in Ingelheim am Rhein, Germany. The early focus was on manufacturing ingredients for pharmacies and the food industry.

Rise to Success

Boehringer Ingelheim has grown into one of the world's largest pharmaceutical companies. Christoph, along with other family members, owns a significant stake in the company. The company has expanded its presence globally, selling products in 130 markets and employing over 54,500 people. The company's focus on respiratory diseases, metabolism, immunology, oncology, and diseases of the central nervous system has contributed to its success.

Key Business Strategies

Boehringer Ingelheim is known for its long-term approach to research and development. The company invests heavily in R&D, with approximately €6.2 billion invested in 2024. Its key therapeutic areas include oncology, respiratory diseases, mental health, and cardio-renal-metabolic diseases. The company's focus on innovation and its commitment to remaining independent, as a private company, allows it to make decisions that benefit patients.

Philanthropy

The Boehringer Ingelheim Cares Foundation provides animal health medicines. Further details on Christoph Boehringer's personal philanthropic endeavors are not available at this time.